Brief: OncoZenge Resolves On Rights Issue Of About SEK 33.3 Mln
26/08/2026 07:09
BRIEF-OncoZenge Resolves On Rights Issue Of About SEK 33.3 Mln Aug 26 (Reuters) - OncoZenge AB (publ) ONCOZ.ST:
SAID ON TUESDAY RESOLVES ON A RIGHTS ISSUE OF ABOUT SEK 33.3 MILLION
SUBSCRIPTION PRICE IS SEK 3.00 PER SHARE
SUBSCRIPTION PERIOD IN RIGHTS ISSUE WILL RUN FROM 4 – 18 SEPTEMBER 2026
RIGHTS ISSUE IS INTENDED TO FINANCE THE EXECUTION OF THE COMPANY'S PHASE III STUDY WITH BUPIZENGE, AS WELL AS RELATED PREPARATORY AND OPERATIONAL ACTIVITIES
Q2 PRELIMINARY NET SALES AMOUNTED TO SEK 5.8 MILLION
PRELIMINARY Q2 OPERATING LOSS AMOUNTED TO SEK 5.4 MILLION
PRELIMINARY Q2 LOSS AFTER TAX AMOUNTED TO SEK 5.7 MILLION
Source text for Workspace: nMFN7LSbhC
Further company coverage: ONCOZ.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))